Anna‐Lotta Hallbeck

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i>TERT</i> promoter mutations and polymorphisms as prognostic factors in primary glioblastoma

Mohamed Ali Mosrati, Annika Malmström, A. Krysztofiak et al. · Oncotarget · 2015 · 125 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Estrogen-induced alterations of spinal cord enkephalin gene expression

Åsa Amandusson, Martin Hallbeck, Anna‐Lotta Hallbeck et al. · Pain · 1999 · 118 citations

Life Sciences, Neurobiology, Neuroscience +17

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Elin Karlsson, Gizeh Pérez‐Tenorio, Risul Amin et al. · Breast Cancer Research · 2013 · 107 citations · Full text

Medicine, Endocrinology, Oncology +17

High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1

Elin Karlsson, Marie Ahnström Waltersson, Josefine Bostner et al. · Genes Chromosomes and Cancer · 2011 · 81 citations · Full text

Medicine, Genetics, Oncology +16